Nanjing Leads Biolabs Co., Ltd.

About Nanjing Leads Biolabs Co., Ltd.

Leads Biolabs, founded in 2012, is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies. The company focuses on addressing diseases that current treatments, such as PD-1/PD-L1 antibodies, cannot treat, aiming to meet unmet medical needs in oncology, autoimmune diseases, and other major diseases in China and globally.

Products & Services

LBL-024:A dual-target bispecific antibody targeting PD-L1 and 4-1BB, the first of its kind in pivotal clinical stage globally, potentially the first approved drug for extrapulmonary neuroendocrine carcinoma (EP-NEC), currently in Phase II trials for small cell lung cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, biliary tract cancer, gastric cancer, and liver cancer. Recognized as a Breakthrough Therapy by NMPA and Orphan Drug by FDA.

LBL-034:A product targeting multiple cancer indications, specifics not fully detailed in the content.

Antibody-Drug Conjugates (ADC):Includes products like LBL-054-ADC (CDH17-TOP1i), LBL-058 (DLL3/CD3-TOP1i), and LBL-061 (EGFR/PD-L1-TOP1i) under Next-Gen ADC development.

Tumor Immunotherapy 2.0 (IO 2.0):Includes products like LBL-007 (LAG3), LBL-019 (TNFR2), and LBL-015 (PD-1/TGF-βR2) focusing on innovative cancer immunotherapies.

CD3 T-cell Engager (TCE):Includes products like LBL-034 (GPRC5D/CD3), LBL-033 (MUC16/CD3), LBL-043 (LILRB4/CD3), LBL-051 (CD19/BCMA/CD3), and LBL-054-TCE (CDH17/CD3) for targeted cancer therapies.

Specialties

Oncology Immunotherapy Antibody-Drug Conjugates (ADC) Tumor Immunotherapy 2.0 (IO 2.0) CD3 T-cell Engager (TCE) Autoimmune Diseases Innovative Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 189000000 MR: - FA: USD 189 million FAN: 189000000	D: 2025-07-25 FD: 2025-07-25	2 investors

Initial Public Offering (IPO) Latest

2025-07-25

$189.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

康

康小强

Founder, Chairman, CEO

S

Steven Rosenberg

Surgery Director

赖

赖寿鹏

Co-Founder and Chief Strategy Officer

凌

凌虹

Senior Vice President and Chief Scientific Officer

蔡

蔡胜利

Chief Medical Officer

左

左鸿刚

Chief Financial Officer

View 3 more team members with Pro

Unlock Full Team Directory

Recent News